Oncology Drug Delivery
Cancer (unspecified)
Pre-clinicalActive
Key Facts
About Sporegen
Sporegen is a pioneering private biotech firm specializing exclusively in Bacillus spore technology, positioning itself as a unique player in the global market. Its platform centers on developing heat-stable mucosal vaccines (SporeVax®), targeted drug delivery for oncology, and novel probiotic strains, aiming to address significant unmet needs in vaccine stability and targeted therapy. The company appears to be in a pre-clinical or early development stage, engaging in contract services to support its R&D while building a proprietary pipeline. Its strategic sponsorship of international conferences indicates an active effort to establish scientific credibility and partnerships within the field.
View full company profileTherapeutic Areas
Other Cancer (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Allogeneic CAR-NK Platform Product | Simnova Biotherapeutics | Phase 1 |
| CAR-engineered NK cells | Glycostem | Pre-clinical |
| Lead Universal CAR-T Candidate | Allogenica | Pre-clinical |
| ADU-1805 | Sairopa | Preclinical |
| PSC-derived NK Cells | HebeCell | Pre-clinical |
| mRNA CAR-γδ-T Cell Platform | PhosphoGam | Pre-clinical |
| R-5780 | Rise Therapeutics | Phase 1 |
| Dendritic Cell-Based Cancer Vaccines | Celica Biomedical | Pre-clinical |
| PD-1/VEGF Program | OncoC4 | Not Disclosed |
| FC001 | FerroptoCure | Phase 1 |
| FC004 | FerroptoCure | Preclinical |